Natural Compounds Targeting Transforming Growth Factor-β: In Silico and In Vitro Study

Inhibition of the tumor-promoting effects of transforming growth factor beta receptor (TGFβR) in carcinogenesis provides a better therapeutic intervention. Various natural compounds, inhibitors of TGFβR have been used for in vitro and in vivo anticancer study. Although very few TGFβR inhibitors are now intensifying in preclinical studies. In this study our aim to investigate TGFβR1, TGFβR2 and TAK1 inhibitor by using molecular docking and in vitro study. Our result revealed that some compounds have better docking energy. Moreover, the effect of two lead molecules epigallocatechin gallate (EGCG) and myricetin on the mRNA expression of TGFβR1 was reported after the 48 hrs treatments in HepG2 and PC3 cancer cell lines. The RT-PCR showed that compound EGCG and myricetin reduced the mRNA expression of TGFβR1 at 80 μM concentration. This molecular docking study provides a better understanding of binding of compounds to the active site of proteins and to summarize the various binding energy, hydrophobic, hydrogen, an electrostatic bond that are decisive for the protein-ligand interactions. Further experimental work will be required for validation of our results.


Pushpendra Singh, Felix Bast, Ravi Shankar Singh

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

  • 9th International Conference on Structural Biology
    September 18-19, 2017 Zurich, Switzerland
  • 2nd International Conference on Biochemistry
    Sep 21-22, 2017, Macau, China
  • International Conference on Chemical Biology
    November 2-3, 2017 Las Vegas, USA
Flyer image

Abstracted/Indexed in

  • Index Copernicus
  • Google Scholar
  • CiteFactor
  • Electronic Journals Library
  • Zoological Records
  • WorldCat
  • Proquest Summons
  • Publons
  • MIAR